SI-BONE Inc (SIBN) — Titan Protect Analysis

SIBN

SI-BONE Inc

Healthcare · ·

$15.12

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$614M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-39.25

Based on estimated future earnings — lower means cheaper

Rev Growth

+11.2%

Year-over-year revenue change

Profit Margin

-8.1%

How much profit the company keeps from each dollar of revenue

ROE

-9.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$25.00

+65% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 9 analysts covering this stock

About SI-BONE Inc

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates

https://si-bone.com

Country: United States Employees: 376 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.318

Positive but modest risk-adjusted returns

Kelly Fraction

0.0198

Marginal edge — very small allocation suggested

Calmar Ratio

0.065

Drawdown risk outweighs the returns — higher risk profile

Annual Return

3.0%

Historical annualised return based on price data

Max Drawdown

-45.8%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.67

Less volatile than the market — more defensive

52W High

$21.89

31% below the year high

52W Low

$11.48

32% above the year low

Avg Volume

702,814

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.39

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

24.00

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

79.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-9.7%

Profit from core operations before interest and tax

Free Cash Flow

$-2,652,125

Negative — the business is spending more than it generates

Revenue (TTM)

$206M

Total revenue over the last 12 months

Net Income

$-16,696,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$32.00

Target Median

$25.00

Target Low

$16.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go